Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.55 Insider Own12.44% Shs Outstand28.49M Perf Week-9.35%
Market Cap35.90M Forward P/E- EPS next Y-0.12 Insider Trans0.00% Shs Float24.95M Perf Month-7.35%
Income-9.29M PEG- EPS next Q-0.07 Inst Own17.94% Short Float2.16% Perf Quarter-33.68%
Sales80.83M P/S0.44 EPS this Y78.84% Inst Trans10.64% Short Ratio2.33 Perf Half Y-48.36%
Book/sh0.76 P/B1.67 EPS next Y68.75% ROA-17.39% Short Interest0.54M Perf Year-43.75%
Cash/sh0.41 P/C3.06 EPS next 5Y38.00% ROE-49.33% 52W Range1.16 - 6.24 Perf YTD-33.33%
Dividend Est.- P/FCF- EPS past 5Y19.45% ROI-32.94% 52W High-79.81% Beta1.14
Dividend TTM- Quick Ratio1.06 Sales past 5Y3.83% Gross Margin10.11% 52W Low8.62% ATR (14)0.09
Dividend Ex-Date- Current Ratio1.32 EPS Y/Y TTM80.81% Oper. Margin-10.01% RSI (14)38.78 Volatility5.91% 7.28%
Employees253 Debt/Eq0.69 Sales Y/Y TTM17.44% Profit Margin-11.49% Recom1.00 Target Price8.00
Option/ShortYes / Yes LT Debt/Eq0.31 EPS Q/Q82.91% Payout- Rel Volume0.71 Prev Close1.29
Sales Surprise4.05% EPS Surprise33.33% Sales Q/Q27.18% EarningsNov 14 BMO Avg Volume231.49K Price1.26
SMA20-4.51% SMA50-17.76% SMA200-49.33% Trades Volume165,270 Change-2.33%
Date Action Analyst Rating Change Price Target Change
Jun-24-19Initiated Piper Jaffray Overweight $10
May-13-19Initiated H.C. Wainwright Buy $11
Nov-08-16Downgrade BofA/Merrill Neutral → Underperform
Mar-01-16Downgrade Stifel Buy → Hold
Aug-13-15Initiated Morgan Stanley Underweight $7
Jan-27-15Reiterated Oppenheimer Outperform $24 → $26
Jan-07-15Initiated Oppenheimer Outperform $24
Aug-14-14Initiated FBR Capital Underperform $6
Dec-19-13Initiated Chardan Capital Markets Buy $22
Nov-06-13Reiterated Summer Street Research Buy
Feb-20-24 06:00PM
Feb-14-24 06:00PM
Feb-08-24 06:00AM
Jan-08-24 07:30AM
Nov-15-23 01:29PM
10:36PM Loading…
Nov-14-23 10:36PM
Nov-07-23 06:00PM
Oct-26-23 06:00PM
Oct-20-23 06:15PM
Oct-18-23 06:00AM
Oct-17-23 06:00AM
Oct-16-23 06:00AM
06:15PM Loading…
Oct-13-23 06:15PM
Oct-03-23 06:15PM
Sep-28-23 06:00AM
Sep-27-23 06:15PM
Sep-21-23 06:15PM
Sep-18-23 11:37AM
Sep-07-23 06:00AM
Aug-15-23 12:29PM
Aug-14-23 10:53PM
Aug-11-23 10:28AM
Aug-10-23 10:00AM
06:00AM Loading…
Aug-09-23 06:00AM
Aug-01-23 06:25PM
Jul-26-23 06:00PM
Jul-21-23 06:15PM
Jul-17-23 06:00AM
Jul-12-23 10:00AM
Jul-11-23 06:00AM
Jul-03-23 09:35AM
Jun-29-23 06:00AM
Jun-28-23 09:26AM
Jun-27-23 12:00PM
Jun-26-23 06:00AM
Jun-23-23 07:43AM
Jun-20-23 06:09AM
Jun-19-23 08:50AM
Jun-08-23 10:18AM
Jun-01-23 08:50AM
May-15-23 08:55PM
May-11-23 08:50AM
May-01-23 06:00AM
Apr-27-23 06:00AM
Apr-25-23 08:50AM
Apr-17-23 07:34AM
Apr-12-23 08:12AM
Apr-11-23 09:41AM
Apr-06-23 08:50AM
Apr-01-23 12:11PM
Mar-30-23 06:00AM
Mar-27-23 06:00AM
Feb-28-23 06:00AM
Feb-16-23 06:00AM
Feb-13-23 07:48AM
Feb-02-23 07:00AM
Dec-13-22 06:00AM
Nov-17-22 05:31AM
Nov-14-22 06:00AM
Nov-09-22 06:00AM
Oct-17-22 06:00AM
Oct-13-22 06:21AM
Sep-14-22 04:15PM
Sep-07-22 08:00AM
Sep-02-22 07:03AM
Aug-30-22 01:27PM
Aug-18-22 08:50AM
Aug-15-22 06:00AM
Aug-03-22 06:00AM
Jun-24-22 08:56AM
Jun-23-22 07:07AM
Jun-22-22 04:02PM
Jun-07-22 08:00AM
Jun-01-22 08:00AM
May-31-22 08:00AM
May-23-22 08:00AM
May-16-22 04:02PM
May-12-22 10:53AM
May-11-22 08:00AM
Apr-29-22 08:25AM
Apr-25-22 08:00AM
Apr-20-22 08:00AM
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.